A comprehensive new systematic review and meta-analysis synthesizes evidence from eight randomized controlled trials, demonstrating that GLP-1 receptor agonists (GLP-1 RAs) like semaglutide and liraglutide can powerfully restore normoglycemia in obese patients with prediabetes, thereby offering a proactive reversal strategy beyond traditional lifestyle interventions. The study was published in the Diabetes/Metabolism: Research And Reviews.
Massive Evidence Base: 14,564 Obese Prediabetic Patients Analyzed
The study scoured PubMed and Cochrane Library for eligible RCTs, ultimately pooling data from 14,564 participants who all had prediabetes complicated by obesity. GLP-1 RAs achieved dramatically superior normoglycemia restoration versus placebo, with a pooled odds ratio of 4.62 (95% CI 2.85-7.49, p<0.00001). This landmark synthesis addresses a critical evidence gap, as prior individual RCTs had not been systematically combined to guide routine clinical practice.
Semaglutide and Liraglutide Shine, Exenatide Falls Short
Semaglutide at 2.4 mg weekly proved highly effective (OR 4.87, 95% CI 2.61-9.09, p<0.00001), delivering consistent results across global studies regardless of cardiovascular disease presence or intervention duration. Liraglutide showed even stronger effects at daily doses of 1.8 mg or 3.0 mg (OR 5.43, 95% CI 1.34-22.04, p=0.02), with the higher 3.0 mg dose maintaining benefits post-intervention. Notably, exenatide failed to demonstrate significant efficacy in this analysis.
Precision Medicine Insights: Sex, Dose, and Durability Factors
Sex-specific patterns emerged: semaglutide excelled particularly in men, while liraglutide performed best in women. Both agents worked independently of patients' mean age and treatment duration, broadening their applicability. However, significant heterogeneity (Q 84.42, p<0.00001; I² 92%, 95% CI 77-97%) arose from variations in country-specific trial performance, semaglutide's lack of post-intervention follow-up data, and subgroup analyses in liraglutide studies.
These findings position GLP-1 RAs as immediate clinical options for obese prediabetic patients while serving as a clear roadmap for future research to refine prediabetes reversal strategies in diverse populations.